INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
11/05/2026
Voltar para busca
Dado oficial do USPTO
ENVARSUS XR
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
64
Atualização mais recente
12/05/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 40, 42, 44
Data de depósito
16/10/2014
Data de registro
27/10/2015
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
11/09/2025
Última transação
12/05/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
707
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
US
Examinador
REINHART, MEGHAN M
Localização atual
Historical data usage
Descrição da marca
The mark consists of three curved horizontal bands above the wording "ENVARSUS XR".
Titulares e representantes
Titulares
Veloxis Pharmaceuticals, Inc.
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S
Representantes
Julia Anne Matheson Potomac Law Group, PLLC
Classificação técnica
Classes Nice
Classe 5Classe 40Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparationsimmunotherapeutic and immunosuppressive preparations for medical use for treatment of transplantation patients; medical preparations and drug delivery systemspharmaceutical modified release systemscontrolled release systemscomprised of tabletsgranulespillssachetspowderscapsulesall of the above for use in the treatment of mental and physical disorderstraumas and emergenciesaddictionsagingallergyimmunologyburnsdiseases of the heart and blood vesselsdental and gum diseasesskin diseasesnutritional and dietary diseasesdiseases of the endocrinological system and pancreatic diseasesdiabetesepidemical diseasesdiseases and afflictions of the gastroenterological systemdiseases of the bloodinfectious diseasesneurological diseasesnephrological diseasesdiseases in the obstetrical and gynaecological fieldcancerophthalmological diseasesdiseases and afflictions affecting the bonesjointscartilage material and musclesdiseases and afflictions of the earnose and threatdiseases and afflictions in the psychiatric fieldpulmonological diseases and afflictionsrheumatismurological diseases and afflictions and generalized pain
Classe 40
Treatment of materialsmillinggrindingmixingcompressingmelting of pharmaceuticalmedicinalbio technical and bacteriological substancespreparationsformulations and solutionsfor use in the pharmaceutical and medical industries
Classe 42
Scientific and technological servicesclinical testing and technology transfer services as well as research and design in connection therewithwithin the medicalpharmaceuticalbio technical and bacteriological areas and providing scientific consultation and information relating thereto; conducting of tests regarding medical applications; packaging design for others; designing and development of medical equipment; designing pharmaceutical medical preparations; development of pharmaceutical formulations; design and development of granulation technology and tablet technology and providing consultation and information thereto; materials testing for the pharmaceutical and medical industries
Classe 44
Medical services; medical and pharmaceutical assistance and consultationmedical and pharmaceutical information servicesproviding medical and scientific research information in the field of pharmaceuticals
Publicações
Histórico de despachos e eventos da marca no USPTO.
64 publicações encontradas
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
11/09/2025
71.P
REGISTERED - PARTIAL SEC 71 ACCEPTED
11/09/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
08/09/2025
ES71
TEAS SECTION 71 RECEIVED
30/05/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
08/11/2024
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
28/10/2024
RNWL
INTERNATIONAL REGISTRATION RENEWED
17/05/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
21/03/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
21/03/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
21/03/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
21/03/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
21/03/2023
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
25/05/2022
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
25/05/2022
C75A
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
25/05/2022
REIN
REINSTATED
25/05/2022
NC71
NOTICE OF CANCELLATION SEC. 71 E-MAILED
24/05/2022
C71T
CANCELLED SECTION 71
23/05/2022
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
17/05/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
28/03/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
28/03/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
28/03/2022
PUM1
OFFICE ACTION ISSUED POU1
22/11/2021
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
17/11/2021
ES75
TEAS SECTION 71 & 15 RECEIVED
26/10/2021
CHLD
CHANGE OF OWNER RECEIVED FROM IB
18/09/2021
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
21/05/2021
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
27/10/2020
NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/02/2020
CORR
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
21/09/2018
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
03/08/2018
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
18/01/2018
NREP
NEW REPRESENTATIVE AT IB RECEIVED
15/09/2016
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
15/07/2016
FICS
FINAL DISPOSITION NOTICE SENT TO IB
19/05/2016
FIMP
FINAL DISPOSITION PROCESSED
19/05/2016
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
27/01/2016
R.PR
REGISTERED-PRINCIPAL REGISTER
27/10/2015
CORR
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
01/09/2015
GPNX
NOTIFICATION PROCESSED BY IB
21/08/2015
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
21/08/2015
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/08/2015
PUBO
PUBLISHED FOR OPPOSITION
11/08/2015
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
05/08/2015
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
05/08/2015
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
22/07/2015
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
08/07/2015
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/07/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/07/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/07/2015
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
26/06/2015
ALIE
ASSIGNED TO LIE
24/06/2015
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
17/06/2015
RFNT
REFUSAL PROCESSED BY IB
13/06/2015
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
26/05/2015
RFRR
REFUSAL PROCESSED BY MPU
26/05/2015
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
24/05/2015
CNRT
NON-FINAL ACTION WRITTEN
23/05/2015
MAFR
APPLICATION FILING RECEIPT MAILED
19/05/2015
DOCK
ASSIGNED TO EXAMINER
16/05/2015
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
15/05/2015
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
15/05/2015
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
14/05/2015
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ENVARSUS XR ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.